{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:15:34Z","timestamp":1758845734239,"version":"3.44.0"},"reference-count":47,"publisher":"Becaris Publishing Limited","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Persistently active noninfectious keratitis can lead to permanent corneal damage and loss of vision. Given the limited treatment options, Acthar Gel, a US FDA-approved treatment for ocular inflammatory conditions, can be a potential therapy. This study evaluated the cost-per-response of Acthar\n            <jats:sup>\u00ae<\/jats:sup>\n            Gel compared with standard of care ([SoC]; adalimumab or infliximab) for noninfectious keratitis from a US healthcare payer perspective over 1\u20133\u00a0years.\n            <jats:bold>Materials &amp; methods:<\/jats:bold>\n            A probabilistic, cohort-level state-transition decision-analytic model was developed to assess the economic value of Acthar Gel. The model simulated the treatment pathway over 3\u00a0years, divided into 3-month cycles. Patients started with active keratitis and received Acthar Gel or SoC. Based on treatment success, patients transitioned between relapse, response and no-response states, with no response potentially leading to complications. Clinical parameters for Acthar Gel were derived from a phase IV open-label study and for SoC from observational studies. Healthcare resource utilization and costs were derived from administrative claims data or published literature.\n            <jats:bold>Results:<\/jats:bold>\n            Over 1\u00a0year, Acthar Gel demonstrated a lower cost per response ($167,928) than SoC, adalimumab ($228,450) and infliximab ($195,083). This benefit for Acthar Gel over SoC was sustained for 2 and 3\u00a0years. Acthar Gel, despite having a higher acquisition cost than SoC, had lower disease management costs and incurred no treatment-related (administration, monitoring or adverse event) costs over 1\u00a0year. Acthar Gel also demonstrated a lower overall cost of care than SoC at 2 and 3\u00a0years. Further, Acthar Gel had higher response rates versus SoC over 1\u20133\u00a0years. Acthar Gel was a dominant treatment option versus SoC at 2 and 3\u00a0years.\n            <jats:bold>Conclusion:<\/jats:bold>\n            From a US healthcare payer perspective, Acthar Gel may be a cost-effective, value-based treatment option for appropriate patients with noninfectious keratitis.\n          <\/jats:p>","DOI":"10.57264\/cer-2025-0088","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T11:59:42Z","timestamp":1752753582000},"source":"Crossref","is-referenced-by-count":0,"title":["Cost-per-response of Acthar Gel versus standard of care for the treatment of noninfectious keratitis: a United States healthcare perspective"],"prefix":"10.57264","volume":"14","author":[{"given":"Jas","family":"Bindra","sequence":"first","affiliation":[{"name":"Falcon Research Group, North Potomac, MD 20878, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishveen","family":"Chopra","sequence":"additional","affiliation":[{"name":"Manticore Consultancy, Bethesda, MD 20814, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Hayes","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater 08807, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Niewoehner","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater 08807, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Panaccio","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater 08807, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J","family":"Wan","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater 08807, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_8_3_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4103\/0301-4738.40358","article-title":"Distinguishing infective versus noninfective keratitis","volume":"56","author":"Srinivasan M","year":"2008","unstructured":"Srinivasan M, Mascarenhas J, Prashanth CN. Distinguishing infective versus noninfective keratitis. Indian J. Ophthalmol. 56(3), 203\u2013207 (2008).","journal-title":"Indian J. Ophthalmol."},{"issue":"4","key":"e_1_3_8_4_2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40123-021-00400-y","article-title":"Repository corticotropin injection (Acthar\u00ae Gel) for refractory severe noninfectious keratitis: efficacy and safety from a Phase IV, multicenter, open-label study","volume":"10","author":"Wirta D","year":"2021","unstructured":"Wirta D, McLaurin E, Ousler G Repository corticotropin injection (Acthar\u00ae Gel) for refractory severe noninfectious keratitis: efficacy and safety from a Phase IV, multicenter, open-label study. Ophthalmol. Ther. 10(4), 1077\u20131092 (2021).","journal-title":"Ophthalmol. Ther."},{"key":"e_1_3_8_5_2","unstructured":"Perez VL Ayres B Toyos M Toyos R. Noninfectious keratitis: an expert panel recommendation. (2019). [cited 2024 December 23]; Available from: https:\/\/v2.evolvemeded.com\/wp-content\/uploads\/2019\/04\/0319JCRS_Noninfectious-keratitis-expert-panel_013119.pdf"},{"issue":"1","key":"e_1_3_8_6_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.emc.2007.10.001","article-title":"The painful eye","volume":"26","author":"Dargin JM","year":"2008","unstructured":"Dargin JM, Lowenstein RA. The painful eye. Emerg. Med. Clin. North Am. 26(1), 199\u2013216; viii (2008).","journal-title":"Emerg. Med. Clin. North Am."},{"issue":"1","key":"e_1_3_8_7_2","doi-asserted-by":"crossref","first-page":"P286","DOI":"10.1016\/j.ophtha.2018.10.023","article-title":"Dry eye syndrome preferred practice pattern\u00ae","volume":"126","author":"Akpek EK","year":"2019","unstructured":"Akpek EK, Amescua G, Farid M Dry eye syndrome preferred practice pattern\u00ae. Ophthalmology 126(1), P286\u2013P334 (2019).","journal-title":"Ophthalmology"},{"issue":"6","key":"e_1_3_8_8_2","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.survophthal.2011.05.003","article-title":"Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease","volume":"56","author":"Durrani K","year":"2011","unstructured":"Durrani K, Zakka FR, Ahmed M Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv. Ophthalmol. 56(6), 474\u2013510 (2011).","journal-title":"Surv. Ophthalmol."},{"issue":"8","key":"e_1_3_8_9_2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/03007995.2018.1474090","article-title":"Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population","volume":"34","author":"Rice JB","year":"2018","unstructured":"Rice JB, White AG, Johnson M Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population. Curr. Med. Res. Opin. 34(8), 1519\u20131527 (2018).","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"e_1_3_8_10_2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/13696998.2018.1474750","article-title":"Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population","volume":"21","author":"Rice JB","year":"2018","unstructured":"Rice JB, White AG, Johnson M Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. J. Med. Econ. 21(9), 846\u2013852 (2018).","journal-title":"J. Med. Econ."},{"key":"e_1_3_8_11_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jare.2018.09.003","article-title":"Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data","volume":"15","author":"Quartuccio L","year":"2019","unstructured":"Quartuccio L, Zabotti A, Del Zotto S Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J. Adv. Res. 15, 87\u201393 (2019).","journal-title":"J. Adv. Res."},{"key":"e_1_3_8_12_2","unstructured":"Mallinckrodt Pharmaceuticals. Acthar\u00ae Gel prescribing information. (1952). (Revised October 2021). Available from: https:\/\/www.acthar.com\/pdf\/Acthar-PI.pdf"},{"key":"e_1_3_8_13_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/CEOR.S410082","article-title":"Acthar Gel (RCI): a narrative literature review of clinical and economic evidence","volume":"15","author":"Wan GJ","year":"2023","unstructured":"Wan GJ, Niewoehner J, Hayes K. Acthar Gel (RCI): a narrative literature review of clinical and economic evidence. Clinicoecon. Outcomes Res. 15, 499\u2013512 (2023).","journal-title":"Clinicoecon. Outcomes Res."},{"key":"e_1_3_8_14_2","first-page":"67","article-title":"Update on the use of systemic biologic agents in the treatment of noninfectious uveitis","volume":"8","author":"Pasadhika S","year":"2014","unstructured":"Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 8, 67\u201381 (2014).","journal-title":"Biologics"},{"issue":"3","key":"e_1_3_8_15_2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for ocular inflammation","volume":"25","author":"Durrani K","year":"2017","unstructured":"Durrani K, Kempen JH, Ying GS Adalimumab for ocular inflammation. Ocul. Immunol. Inflamm. 25(3), 405\u2013412 (2017).","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"8","key":"e_1_3_8_16_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/OPX.0b013e3181824e0d","article-title":"Clinically important difference in dry eye: change in IDEEL-symptom bother","volume":"85","author":"Fairchild CJ","year":"2008","unstructured":"Fairchild CJ, Chalmers RL, Begley CG. Clinically important difference in dry eye: change in IDEEL-symptom bother. Optom. Vis. Sci. 85(8), 699\u2013707 (2008).","journal-title":"Optom. Vis. Sci."},{"key":"e_1_3_8_17_2","first-page":"69","article-title":"The efficacy and safety of adalimumab in ocular inflammatory disease","volume":"5","author":"Arcinue CA","year":"2015","unstructured":"Arcinue CA, Durrani K, Artornsombudh P The efficacy and safety of adalimumab in ocular inflammatory disease. Orphan Drugs 5, 69\u201374 (2015).","journal-title":"Orphan Drugs"},{"issue":"9","key":"e_1_3_8_18_2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bjophthalmol-2018-312767","article-title":"Long-term efficacy and tolerability of TNFalpha inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study","volume":"105","author":"Sharma SM","year":"2021","unstructured":"Sharma SM, Damato E, Hinchcliffe AE Long-term efficacy and tolerability of TNFalpha inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study. Br. J. Ophthalmol. 105(9), 1256\u20131262 (2021).","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"e_1_3_8_19_2","doi-asserted-by":"crossref","first-page":"e000819","DOI":"10.1136\/bmjophth-2021-000819","article-title":"Adalimumab in patients with vision-threatening uveitis: real-world clinical experience","volume":"6","author":"Tang Lee Say TL","year":"2021","unstructured":"Tang Lee Say TL, Yang V, Fingret JM Adalimumab in patients with vision-threatening uveitis: real-world clinical experience. BMJ Open Ophthalmol. 6(1), e000819 (2021).","journal-title":"BMJ Open Ophthalmol."},{"key":"e_1_3_8_20_2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings LEM","year":"2022","unstructured":"Eurelings LEM, Missotten T, van Velthoven MEJ Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy. Am. J. Ophthalmol. 240, 194\u2013204 (2022).","journal-title":"Am. J. Ophthalmol."},{"issue":"7","key":"e_1_3_8_21_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archopht.125.7.895","article-title":"Infliximab therapy for the treatment of refractory ocular inflammatory disease","volume":"125","author":"Sobrin L","year":"2007","unstructured":"Sobrin L, Kim EC, Christen W Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch. Ophthalmol. 125(7), 895\u2013900 (2007).","journal-title":"Arch. Ophthalmol."},{"issue":"1","key":"e_1_3_8_22_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up","volume":"121","author":"Kruh JN","year":"2014","unstructured":"Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 121(1), 358\u2013364 (2014).","journal-title":"Ophthalmology"},{"issue":"1","key":"e_1_3_8_23_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12886-023-02987-1","article-title":"Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis","volume":"23","author":"Liu W","year":"2023","unstructured":"Liu W, Bai D, Kou L. Comparison of infliximab with adalimumab for the treatment of non-infectious uveitis: a systematic review and meta-analysis. BMC Ophthalmol. 23(1), 240 (2023).","journal-title":"BMC Ophthalmol."},{"issue":"4","key":"e_1_3_8_24_2","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.rdc.2007.08.002","article-title":"Scleritis and peripheral ulcerative keratitis","volume":"33","author":"Galor A","year":"2007","unstructured":"Galor A, Thorne JE. Scleritis and peripheral ulcerative keratitis. Rheum. Dis. Clin. North Am. 33(4), 835\u201354; vii (2007).","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"1","key":"e_1_3_8_25_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1001\/archopht.120.1.15","article-title":"Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy","volume":"120","author":"Sainz de la Maza M","year":"2002","unstructured":"Sainz de la Maza M, Foster CS, Jabbur NS, Baltatzis S. Ocular characteristics and disease associations in scleritis-associated peripheral keratopathy. Arch. Ophthalmol. 120(1), 15\u201319 (2002).","journal-title":"Arch. Ophthalmol."},{"issue":"7","key":"e_1_3_8_26_2","doi-asserted-by":"crossref","first-page":"A507","DOI":"10.1016\/j.jval.2011.08.1497","article-title":"PSS32 Impact of Dry Eye on Everyday Life (IDEEL) - Symptom Bother: estimating cut-off scores for dry eye severity groups","volume":"14","author":"Acaster S","year":"2011","unstructured":"Acaster S, Verboven Y, Begley C PSS32 Impact of Dry Eye on Everyday Life (IDEEL) - Symptom Bother: estimating cut-off scores for dry eye severity groups. Value Health 14(7), A507\u2013A508 (2011).","journal-title":"Value Health"},{"key":"e_1_3_8_27_2","unstructured":"Micromedex\u00ae RED BOOK\u00ae. (2025)."},{"key":"e_1_3_8_28_2","unstructured":"AbbVie Inc. HUMIRA\u00ae (adalimumab): prescribing information. (2024). Available from: https:\/\/www.rxabbvie.com\/pdf\/humira.pdf"},{"key":"e_1_3_8_29_2","unstructured":"Janssen Biotech Inc. REMICADE (infliximab): prescribing information. (2021). Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf"},{"issue":"8","key":"e_1_3_8_30_2","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.clinthera.2017.06.007","article-title":"Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting","volume":"39","author":"Schmier J","year":"2017","unstructured":"Schmier J, Ogden K, Nickman N Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Clin. Ther. 39(8), 1600\u20131617 (2017).","journal-title":"Clin. Ther."},{"issue":"11","key":"e_1_3_8_31_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/jhm.13214","article-title":"Association of hospital spending with care patterns and mortality in patients hospitalized with community-acquired pneumonia","volume":"18","author":"Latif M","year":"2023","unstructured":"Latif M, Guo N, Tereshchenko LG, Rothberg MB. Association of hospital spending with care patterns and mortality in patients hospitalized with community-acquired pneumonia. J. Hosp. Med. 18(11), 986\u2013993 (2023).","journal-title":"J. Hosp. Med."},{"issue":"1","key":"e_1_3_8_32_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/j.gastro.2018.08.063","article-title":"Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018","volume":"156","author":"Peery AF","year":"2019","unstructured":"Peery AF, Crockett SD, Murphy CC Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology 156(1), 254\u2013272; e11 (2019).","journal-title":"Gastroenterology"},{"issue":"12","key":"e_1_3_8_33_2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1097\/CCM.0000000000003342","article-title":"Epidemiology and costs of sepsis in the United States-an analysis based on timing of diagnosis and severity level","volume":"46","author":"Paoli CJ","year":"2018","unstructured":"Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and costs of sepsis in the United States-an analysis based on timing of diagnosis and severity level. Crit. Care Med. 46(12), 1889\u20131897 (2018).","journal-title":"Crit. Care Med."},{"issue":"6","key":"e_1_3_8_34_2","doi-asserted-by":"crossref","first-page":"ofae267","DOI":"10.1093\/ofid\/ofae267","article-title":"The Incidence of skin and soft tissue infections in the United States and associated healthcare utilization between 2010 and 2020","volume":"11","author":"Vella V","year":"2024","unstructured":"Vella V, Derreumaux D, Aris E The Incidence of skin and soft tissue infections in the United States and associated healthcare utilization between 2010 and 2020. Open Forum Infect. Dis. 11(6), ofae267 (2024).","journal-title":"Open Forum Infect. Dis."},{"issue":"10","key":"e_1_3_8_35_2","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.3201\/eid2910.230314","article-title":"Estimated costs of 4-month pulmonary tuberculosis treatment regimen, United States","volume":"29","author":"Winston CA","year":"2023","unstructured":"Winston CA, Marks SM, Carr W. Estimated costs of 4-month pulmonary tuberculosis treatment regimen, United States. Emerg. Infect. Dis. 29(10), 2102\u20132104 (2023).","journal-title":"Emerg. Infect. Dis."},{"issue":"4","key":"e_1_3_8_36_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/OLQ.0000000000001371","article-title":"Lifetime medical costs of genital herpes in the United States: estimates from insurance claims","volume":"48","author":"Eppink ST","year":"2021","unstructured":"Eppink ST, Kumar S, Miele K, Chesson HW. Lifetime medical costs of genital herpes in the United States: estimates from insurance claims. Sex. Transm. Dis. 48(4), 266\u2013272 (2021).","journal-title":"Sex. Transm. Dis."},{"issue":"8","key":"e_1_3_8_37_2","doi-asserted-by":"crossref","first-page":"e0182577","DOI":"10.1371\/journal.pone.0182577","article-title":"The burden of septic arthritis on the U.S. inpatient care: a national study","volume":"12","author":"Singh JA","year":"2017","unstructured":"Singh JA, Yu S. The burden of septic arthritis on the U.S. inpatient care: a national study. PLoS ONE 12(8), e0182577 (2017).","journal-title":"PLoS ONE"},{"key":"e_1_3_8_38_2","doi-asserted-by":"crossref","first-page":"e544","DOI":"10.1097\/JU.0000000000003277.20","article-title":"MP39-20 Cost of urinary tract infections with and without antibiotic resistance in the United States from 2012\u20132019","volume":"209","author":"Nagpal M","year":"2023","unstructured":"Nagpal M, Chu J, Dobberfuhl A. MP39-20 Cost of urinary tract infections with and without antibiotic resistance in the United States from 2012\u20132019. J. Urol. 209, e544 (2023).","journal-title":"J. Urol."},{"issue":"7","key":"e_1_3_8_39_2","doi-asserted-by":"crossref","first-page":"A503","DOI":"10.1016\/j.jval.2015.09.1428","article-title":"Recent trends in anaphylaxis-related hospitalization in the United States","volume":"18","author":"Candrilli S","year":"2015","unstructured":"Candrilli S, Kurosky SK. Recent trends in anaphylaxis-related hospitalization in the United States. Value Health 18(7), A503 (2015).","journal-title":"Value Health"},{"issue":"7","key":"e_1_3_8_40_2","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/annonc\/mdp535","article-title":"Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab","volume":"21","author":"Foley KA","year":"2010","unstructured":"Foley KA, Wang PF, Barber BL Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Ann. Oncol. 21(7), 1455\u20131461 (2010).","journal-title":"Ann. Oncol."},{"issue":"11","key":"e_1_3_8_41_2","doi-asserted-by":"crossref","first-page":"e003471","DOI":"10.1136\/bmjopen-2013-003471","article-title":"The economic burden of visual impairment and blindness: a systematic review","volume":"3","author":"Koberlein J","year":"2013","unstructured":"Koberlein J, Beifus K, Schaffert C, Finger RP. The economic burden of visual impairment and blindness: a systematic review. BMJ Open 3(11), e003471 (2013).","journal-title":"BMJ Open"},{"key":"e_1_3_8_42_2","unstructured":"Bentley TS Ortner N. 2020 U.S. organ and tissue transplants: cost estimates discussion and emerging issues. (2020). [cited 2025 January 9]; Available from: https:\/\/www.milliman.com\/en\/insight\/2020-us-organ-and-tissue-transplants"},{"key":"e_1_3_8_43_2","volume-title":"Total expenses, total utilization, and sources of payment for outpatient prescription opioids in the U.S. adult civilian noninstitutionalized population, 2017, in Statistical Brief (Medical Expenditure Panel Survey (US))","author":"Ding Y","year":"2001","unstructured":"Ding Y, Miller GE. Total expenses, total utilization, and sources of payment for outpatient prescription opioids in the U.S. adult civilian noninstitutionalized population, 2017, in Statistical Brief (Medical Expenditure Panel Survey (US)). Rockville (MD) (2001)."},{"issue":"11","key":"e_1_3_8_44_2","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/j.clinthera.2019.09.011","article-title":"Predictors of high-cost patients with noninfectious inflammatory eye diseases","volume":"41","author":"Nelson WW","year":"2019","unstructured":"Nelson WW, Rice JB, White AG Predictors of high-cost patients with noninfectious inflammatory eye diseases. Clin. Ther. 41(11), 2331\u20132342 (2019).","journal-title":"Clin. Ther."},{"issue":"4","key":"e_1_3_8_45_2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/ICO.0000000000002893","article-title":"Opioid prescribing patterns for ulcerative keratitis","volume":"41","author":"Thibodeau AR","year":"2022","unstructured":"Thibodeau AR, Niziol LM, Tannen BL, Ballouz D, Woodward MA. Opioid prescribing patterns for ulcerative keratitis. Cornea 41(4), 484\u2013490 (2022).","journal-title":"Cornea"},{"issue":"5","key":"e_1_3_8_46_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ophtha.2019.11.005","article-title":"Prescribing patterns and costs associated with postoperative eye drop use in Medicare beneficiaries undergoing cataract surgery","volume":"127","author":"Zafar S","year":"2020","unstructured":"Zafar S, Wang P, Schein OD Prescribing patterns and costs associated with postoperative eye drop use in Medicare beneficiaries undergoing cataract surgery. Ophthalmology 127(5), 573\u2013581 (2020).","journal-title":"Ophthalmology"},{"issue":"2","key":"e_1_3_8_47_2","first-page":"123","article-title":"Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans","volume":"17","author":"Vlahiotis A","year":"2011","unstructured":"Vlahiotis A, Devine ST, Eichholz J, Kautzner A. Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans. J. Manag. Care Pharm. 17(2), 123\u2013132 (2011).","journal-title":"J. Manag. Care Pharm."},{"key":"e_1_3_8_48_2","unstructured":"US Bureau of Labor Statistics. CPI for all urban consumers. Medical care in U.S. city average all urban consumers seasonally adjusted. (2024). Available from: https:\/\/data.bls.gov\/"},{"issue":"26","key":"e_1_3_8_49_2","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter ME","year":"2010","unstructured":"Porter ME. What is value in health care? N. Engl. J. Med. 363(26), 2477\u20132481 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2025-0088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:51:43Z","timestamp":1758797503000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2025-0088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.57264\/cer-2025-0088"],"URL":"https:\/\/doi.org\/10.57264\/cer-2025-0088","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"e250088"}}